A Study for Patients With Type 2 Diabetes

• Status: Completed
• Trial end date: 2011-01-01

Summary

Comparison of fasting blood glucose levels in patients with Type 2 diabetes after 12 weeks of treatment with a new basal insulin analog or with insulin glargine.

• Phase: Phase 2

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Insulin; Insulin Glargine; Insulin, Globin Zinc